… Inhibitors of the EGFR have emerged as promising anticancer agents and two main … tyrosine
kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors …

… first inhibitor of tyrosine kinase activity to be described was quercetin, which is able to block
several tyrosine kinases … Quercetin was also the first tyrosine kinase inhibitor (TKI) tested in a …

… Mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors. Multiple mechanisms have been elucidated in human samples and preclinical …

… tyrosine kinase inhibitor compounds with sufficient potency, bioavailability and selectivity
against this subfamily of receptor tyrosine kinases. … the first of these inhibitor compounds to gain …

… growth factor receptor (EGFR) has been selected as a potential … Because growth factor
networks are redundant, … (P13-Kinase), growth factor receptor binding protein 2 (Grb2, Src family …

… Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) … of
the hepatocyte growth factor and suppression of Bcl-2-like protein 11 expression may lead to …

… Such oncogen ic homologs provide invaluable clues to the mechanisms of normal growth
factor receptors, in addition to enhancing our understanding of cellular transformation and …

… -molecule tyrosine kinase inhibitors represent one of the most promising classes of anticancer
agents. Here, we describe the status of small-molecule EGFR tyrosine kinase inhibitors in …

… Our current view for indication of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) in Japanese patients with lung cancer. Numbers in each patient subset …

… Several articles have extensively reviewed the role of the epidermal growth factor receptor
(… MOA of EGFR tyrosine kinase inhibitors (TKIs). THE ErbB RECEPTORS FORM A COMPLEX …